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The efficacy and adequacy of continuous
ambulatory peritoneal dialysis
George Wu, Donald Kim, Dimitrios G Oreopoulos
SUMMARY
Since it was introduced in 1976, continuous ambulatory peritoneal dialysis
(CAPD) has won acceptance in many centres and it is now regarded as an
important alternative to haemodialysis. CAPD patients have comparable and, in
some circumstances, better survival than those on chronic haemodialysis. It is
indicated particularly in patients with diabetes mellitus, cardiovascular instability
and at the extremes of life. The success of kidney transplantation is similar in
those maintained on CAPD and on haemodialysis. CAPD also achieves satis-
factory physical and psychological rehabilitation, and the quality of life, including
the level of sexual function, is similar during CAPD and haemodialysis. Women
on CAPD menstruate more often than those on haemodialysis. CAPD provides
adequate clearance of metabolic wastes, maintains fluid balance and ameliorates
neurotoxic cognitive dysfunction. CAPD gives control of hypertension and
anaemia which is superior to that on haemodialysis. Neuropathy remains stable
but osteitis fibrosa seems to progress. CAPD is the most economical of the
various formsof dialysis. We conclude that CAPD is an adequate form ofreplace-
ment and should be made available in every nephrology centre providing
treatment for patients with end-stage renal disease.
INTRODUCTION
Continuous ambulatory peritoneal dialysis (CAPD) was introduced in 19761 and
soon became one of the most popular modes of home dialysis. There is no single
qualitative or quantitative index by which to evaluate the efficacy of CAPD. This
paper will present evidence to suggest that CAPD provides adequate dialysis
according to the following criteria:
1) It sustains life in patients with end-stage renal disease (ESRD).
2) It maintains patients in a satisfactory condition while awaiting a kidney
transplant, and it does not adversely affect the results of transplantation; if
the latter fails, CAPD can be recommenced after transplant nephrectomy.
3) It provides a satisfactory quality oflife as indicated by adequate rehabilitation
and sexual activity.
4) It can sustain children, and facilitate their growth.
5) It can provide adequate biochemical control.
6) It can arrest or even ameliorate uraemic complications.
Furthermore, it is an inexpensive process.
In addition the adequacy of CAPD will be demonstrated by comparing its
results with those of the more firmly established dialysis modality - chronic
haemodialysis.
Department of Medicine, Toronto Western Hospital, and University of Toronto.
George Wu, MD, FRCP(C), Lecturer.
Donald Kim, MD, FRCP(C).
Dimitrios G Oreopoulos, MD, PhD (Belfast), FRCP(C), FACP, Professor of Medicine.
(© The Ulster Medical Society, 1985.Continuous ambulatory peritoneal dialysis (2) S49
SURVIVAL ON CAPD
In Toronto Western Hospital, survival at
the end of 1, 2, 3, 4, 5 years is 90%,
80%, 70%, 65% and 46% respectively
(Fig 1). The attrition rate is about 10%
per year.
Data concerning the various forms of
dialysis used in Canada in 1981-19822
shows that the non-diabetic CAPD
patients (n = 596), who were, on
average, 4 years older than those on
haemodialysis, have a 90% and 80%
chance of survival at the end of 12 and
24 months respectively. During this
same period, the non-diabetics on
haemodialysis (n = 1 161) had a survival
rate of 85% and 75%. Atthe end oftwo
years, the probability ofdropout (failures
and deaths together) was 48% on
CAPD, and 41 % on haemodialysis.
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Fig. 1. Cumulative patient and technique
survival in 257 CAPD patients at the Toronto
Western Hospital.
The European Dialysis and Transplant Association (EDTA) studied a large
numberofCAPD patientsand compared them with patientson other replacement
therapies.3 They had 3607 patients registered on CAPD by the end of December
1982. Their data showed thatthe survival ofCAPD patients in various age groups
is comparable with that on other modalities (Tables la and lb). In all age groups,
survival of diabetics on CAPD at one year was consistently better than that of the
general diabetic population on renal replacement therapy, although no statistical
analysis was provided.
TABLE Ia
One-year survival among non-diabetic patients with end-stage renal disease
being treated with kidney replacement therapy in Europe
Therapy (% ofpatients alive)
Any kidney
Cadaveric replacement
Age (year) Haemodialysis(l) CAPD transplant therapy(2)
15 - 34 97 93 93
35 -44 96 90 91
45 - 54 90 92 84 90
55 -64 84 77 85
65 75 77 76
(1) Value extracted from a figure.
(2) Irrespective of any subsequent changes in the mode of treatment.
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TABLE Ib
One-year survival among diabetic patients with end-stage renal disease
being treated with kidney replacement therapy in Europe
Therapy (% ofpatients alive)
Any kidney
Cadaveric replacement
Any (year) Haemodialysis(1) CAPD transplant therapy(2)
15 -34 92 72 77
35 -44 77 77 73
45 -54 72 80 63 71
55-64 71 70
65 58
(1) Number extracted from a figure.
(2) Irrespective of any subsequent changes in the mode of treatment.
Ofthe factors which influence survival, the most importantare age, diabetes, pre-
existing cardiovascular disease and depression at the onset oftreatment. Survival
at four years for patients younger than 40 years, those between 40 and 59, and
those olderthan 60 were 95%, 72% and 40% respectively. This is not surprising
because, in general, younger patients are healthier and have fewer cardiovascular
and metabolic complications.
Patients with end-stage renal failure due to diabetes are particularly difficult to
treat. They have multiple system involvement andsignificant impairmentofvisual
acuity. Their survival on intermittent peritoneal dialysis is poor.4 Many diabetics
with end-stage renal failure, even those who are blind, are now treated with
CAPD.5 At the Toronto Western Hospital, the overall survival of the insulin-
dependent (Type I) diabetics on CAPD is 89%, 65%, 58% and 58% at the end
of 1, 2, 3 and 4 years, compared with 92%, 81%, 72% and 66% for non-
diabetics.
In a previous study,6 we demonstrated that patients with pre-existing cardio-
vascular disease have a lowersurvival than those who do not have cardiovascular
disease at the start of CAPD.
In a selected group of low-risk patients (i.e. those aged between 20 and 60
without co-existing systemic diseases such as diabetes mellitus, vasculitis,
scleroderma, amyloidosis and multiple myeloma and without pre-existing cardio-
vascular complications such as angina pectoris, myocardial infarction and
hypertensive cardiomyopathy), we found a 100% survival at the end of 4 years
on CAPD (Fig 2).
CAPD AND KIDNEY TRANSPLANTATION
Among CAPD patients awaiting transplantation, the principal risk factors which
are related to peritoneal dialysis and may affect the outcome are peritonitis,
perforation of peritoneal cavity during the procedure and catheter skin exit
infections. Patient and graft survival are comparable in patients who were
maintained on haemodialysis or peritoneal dialysis before transplantation.7
Problems with the catheter and exit-site are uncommon and can be managed
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without complications.8 If peritonitis
develops in the post-operative period, it
can be treated easily with antibiotics and
early removal of the catheter. Immuno-
suppressive therapy does not increase the
incidence and severity of peritonitis.
Patients in whom renal transplantation
fails can be treated again by CAPD. Of 22
such patients who returned to our CAPD
programme, survival was 84% at the end
of the first year, and 73% at the end of
the second year. Thesefigures are slightly
lower than those for the general CAPD
population, probably because these
patients had multiple problems, such as
rejection, intensive treatment with
cytotoxic drugs and repeated episodes of
severe infection. These patients did not
have a higher incidence ofperitonitis than
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Fig. 2. Survival of low risk patients on CAPD (See text for the definition of 'low-risk')
QUALITY OF LIFE
It is difficult to measure quality of life. Sometimes it can only be inferred from the
patient's activity level, employment status, sexual activity and relationship with
the other family members.
A review ofthe level of rehabilitation among the patients in our programme atthe
end of 1983 (Table 11), showed that 38% were working full-time - either in
employment or as homemakers with normal activity. The level of the rehabili-
tation in workscale is low because a large proportion ofourpatients were overthe
retirement age; this result is not significantly different from that reported for a
large population of ESRD patients on haemodialysis.9 Fifty-four per cent of our
patients claimed that their daily activity was normal. Among the 59 young
TABLE II
Rehabilitation of86 patients on Toronto Western Hospital CAPD programme
on 31 December, 1983
Occupational status (%) Daily activity (%)
Full-time 12 (14) Normal 54 (63)
Part-time 0 Restricted 26
Sick leave 6 Requires care 5
Homemaker Confined to bed 0
(normal activity) 21 (24)
Homemaker (restricted) 10
Unemployed 1 1
Retired (normal activity) 1 1 (13)
Retired (restricted) 14
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patients without systemic complications (as defined previously), 64% were fully
rehabilitated and 85% had normal daily activities.
In a retrospective multicentre survey of the demography, physical activity and
employment status of CAPD and haemodialysis patients carried out by question-
naires, Fragola et al'0 found that 68% of the non-diabetic and 48% of the
diabetic CAPD patients were capable of greater activities than self-care. Corres-
ponding figures for haemodialysis patients were 59% and 23% respectively.
These differences were statistically significant.
Churchill et al tried a new approach in measuring the quality of life in dialysis and
transplant patients which they have called the 'time trade-off' technique."1 The
patients were given a hypothetical choice: they could either continue in their
present state of health with its physical, emotional and social limitations for a
lifetime (t) (determined from actuarial data) or they could choose a shorter time
(x) in a state offull health except for the normal ageing process. The value (x/t) is
an index ofthe health state or the perceived quality oflife for the individual. They
found that the mean values for hospital-based haemodialysis, CAPD and
transplantation patients were 0.57, 0.57 and 0.80 respectively.
Sexual function
Sexual dysfunction is common in patients with chronic renal failure and those on
dialysis.'2 The patient and the partner are under constant physical and psycho-
logical stress. They have to adjust every aspect of daily living to the restraint-of
dialysis. The patient's illness may force the spouse to change roles in earning
income, assuming responsibility for housework and raising of the family. This
change produces great stress, and frequently the patient may not be able to
accept the new role. In addition to these psychological factors, a concomitant
abnormal metabolic and hormonal status may produce a sexual dysfunction.
Abnormal sex hormone homeostasis has been implicated in patients with renal
failure.13'5 Sexual dysfunction has been attributed to impaired pituitary function
with inadequate levels of FSH and LH, high level of prolactin and low level of
zinc.16, 17 In addition, CAPD patients may find the body image distorted by the
presence ofthe catheter, the empty bag and the dialysis solution in the abdomen,
and this may impair libido further. Burton etal18showed thatsubstantial numbers
ofdialysis patients, whether on haemodialysis or CAPD, reported marriage strain,
sexual dysfunction, and altered perceptions of sexual identity and attractiveness.
However, patients undergoing haemodialysis complained significantly more often
about all four kinds of marital-sexual stress than did patients on CAPD.
Resumption ofmenses
Most women do not menstruate while on maintenance haemodialysis. Galler et
al'9 reported that 86% of those on CAPD and only 25% of those on haemo-
dialysishaveregularmenses. Frequently, amenorrhoeicfemalesonhaemodialysis
resume menstruation after being started on CAPD. Even though the ovulatory
cycle is still rare, resumption of menstruation often has a beneficial psychological
effect on women with renal disease.
Pregnancy is still a rare event among women on dialysis and successful
pregnancies with a live birth are even more unlikely. Kioko et al20 described a
successful pregnancy in a 26-year-old woman with advanced diabetic nephro-
pathy treated with CAPD. The pregnancy was carried to 34 weeks and an infant
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of 1.7 kg was delivered by Caesarean section. Two other women on CAPD
became pregnant,21 22 but both ended in spontaneous abortion at 13 and 32
weeks.
CAPD IN CHILDREN WITH ESRD
CAPD has made an important contribution to the treatment of children
with ESRD, especially the very small ones.23
Baum et a124 compared two groups of children, one treated by CAPD and the
other by haemodialysis. In the childrenon CAPD, protein and caloric intakes were
higher and the growth rate was slightly faster but the difference did not reach
statistical significance. CAPD treatment was more cost-effective than haemo-
dialysis. In another report,25 Balfe reported that children treated by CAPD grew
faster than those treated by haemodialysis, although the growth was still not as
good as in children with successful renal transplants. It appears that children with
end-stage renal failure would have a growth rate which would approach normal, if
one controlled hyperparathyroidism and gave optimal nutrition. Kohaut,26 who
described significant catch-up growth in children treated with CAPD, stressed the
importance of careful and intensive management of hyperparathyroidism and
close attention to nutritional needs; the children in the latterstudy ingested about
2g of protein/kg of bodyweight. Thus CAPD makes it possible to liberalise the
diet and fluid intake in a group ofpatients who are particularly difficult to manage.
BIOCHEMICAL CONTROL
In most individuals CAPD with eight litres per day (i.e. 4 x 2 litre exchanges)
stabilises the biochemical abnormalities (Table 111). The following observations
about serum potassium and phosphorus may be of particular interest:
Potassium: Each dayCAPDremovesapproximately 25 to35 mmolofpotassium,
and some CAPD patients become hypokalaemic despite a liberal potassium
intake (60-80 mmol/day). This may be due to increased potassium loss from the
gastrointestinal tract,27 or intracellular accumulation of this ion associated with
absorption ofglucose from the dialysate or urinary loss, e.g. in a patient receiving
large doses of furosemide.
Phosphorus: CAPD alone does not remove enough phosphorus to keep the
serum phosphorus at normal levels. Most patients also require a phosphorus-
restricted diet and/ora phosphorus binder but ina dose smallerthan that required
in haemodialysis. Aluminum binders are unpalatable, mayaggravate constipation
and even precipitate diverticulitis, and may contribute to the development of
osteomalacia and dialysis dementia. The risk of these complications can be
minimised by using a magnesium-free dialysate in combination with phosphorus
binders containing a mixture of magnesium hydroxide and aluminium hydroxide.
This mixture. which has a mild laxative effect, binds phosphorus with a lower
dose of aluminium hydroxide and is more palatable.
FLUID INTAKE
One can be more liberal with fluid intake in CAPD than in haemodialysis because
ultrafiltration is continuous and thirst is decreased. Large volumes of ultrafiltrate
can be removed by the use of hypertonic (4.25% dextrose) exchanges -
600-800 ml/exchange. Recently, however, we have been advising our patients
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TABLE III
The blood biochemical values ofpatients on four x 2 litre exchanges/day,
after one year of CAPD treatment
Four bag days
Mean ±std dev.
Blood urea nitrogen (mg%) 54.1 ±-16.6
Creatinine (mg%) 11.5 1.5
Calcium (mg%) 9.3 ±0.64
Phosphorus (mg%) 4.2 ±0.75
Uric acid mg% 6.9 ±1.03
Total protein gm% 6.3 ±0.93
Albumin gm% 3.2± 0.44
Potassium mEq/1 4.0 ±0.59
Cholesterol mg% 237.2 ±80.7
Triglycerides mg% 299.3 ±134.2
Haemoglobin gm% 9.3 ±1.9
Platelets (x 100/mm3) 501.3 ± 106.41
against the liberal use of water because frequent hypertonic exchanges lead. to
increased glucose absorption with all its consequences - lipid abnormalities,
obesity and possibly damage to the peritoneum.
CAPD AND URAEMIC COMPLICATIONS
Control ofhypertension
Blood pressure is controlled easily in patients on CAPD and usually returns to
normal during the first few weeks. We measured blood pressure in 197 patients,
before and after CAPD. Before starting CAPD, 77% of the patients had hyper-
tension, defined as a systolic >160 mmHg and/or a diastolic>90 mmHg; all
were on antihypertensive medication and only 23% had anormal blood pressure.
While on CAPD, 74% of those who initially were hypertensive became normo-
tensive and required no further medication. Another 20% had normal blood
pressureon antihypertensive medication, butthedosage wassmallerthan before.
Of the patients who initially were hypertensive, 6% remained hypertensive.
Because of the ease with which hypertension is brought under control occasion-
ally we have started CAPD on patients suffering from intractable hypertension,
even though their renal failure had not advanced to the point where they required
dialysis.
Leenen et a128 studied with serial M mode echocardiography 17 CAPD patients
all ofwhom had a history ofhypertension and had echocardiographic evidence of
increased LV (left-ventricular) mass related to both concentric and eccentric
hypertrophy. On CAPD the blood pressure returned to normal consistently. In 14
of 17 patients, left-ventricular mass decreased as a result ofreduction in both LV
wall thickness and LV dimension. Repeat echocardiography showed improve-
ment in three of four patients who initially had impaired LV function. These
workers concluded that CAPD improves LV hypertrophy by normalising pressure
and volume overload of the left ventricle.
© The Ulster Medical Society, 1985.
S54Continuous ambulatory peritoneal dialysis (2)
Control of anaemia
The average haematocrit is 30-35% and the average haemoglobin is about 9-10
g/dl in the CAPD patients. These patients require transfusions and anabolic
steroids less frequently than those on haemodialysis.29 Frequently it has been
observed that haemoglobin and haematocrit increase in patients transferred from
haemodialysis to CAPD.30
In 34 patients on CAPD, DePaepe et a131 found a significant increase in haemo-
globin and haematocrit in the first 6 months of CAPD. The elevated haematocrit
represents a combination of true increase in red cell mass and a decrease in
plasma volume. The serum PTH and ferritin remained unchanged. Zappacosta
also found a significant increase in haematocrit in four of nine CAPD patients,32
and it appears that those who respond to CAPD are those who have high
erythropoietin levels. Three ofthe four responders had polycystic kidney disease.
As yet we have no explanation for the improvement of erythropoiesis in patients
on CAPD. Lamperi et al confirmed the improved erythropoiesis by in vitro studies
of the colony-formation capacity of the bone marrow cells but found no
correlation between the rise in haematocrit levels and the serum erythropoietin
levels.33 They suggested that the improved erythropoiesis results from the
removal by CAPD oftoxicfactor(s), which suppress bone marrow. Hefti et al, who
studied red cell survival in 11 CAPD patients, found that the reduction in red cell
survival still persisted - the mean 51 Cr red cell half-life was 20 days.34
Pericarditis
The incidence of pericarditis in patients with ERSD is reported to be 32% -
41 %,35 36 but, with earlier and more effective dialysis, uraemic pericarditis can be
prevented. The incidence of uraemic pericarditis among patients on chronic
haemodialysis varies from 10% to 18N.37,38 Pericarditis isan infrequent complic-
ation among our CAPD patients. Since the beginning of our programme, we have
encountered only 9 episodes of pericarditis among 257 patients. None of these
developed tamponade; one developed pericarditis following a reactivation of
systemic lupus erythematosus.
Neuropathy
Neuropathy was identified as a complication of advanced renal failure in 1961,39
but its cause remains an enigma. Frequently it has been attributed to an
accumulation of uraemic toxins of middle molecular size.40 Initially we hoped that
CAPD patients might have a lower incidence and slower progression of uraemic
neuropathy than those on haemodialysis or intermittent PD because it achieves a
better clearance of middle molecules.
We have studied the electrophysiological parameters in 23 non-diabetics and 6
diabetics who have been on CAPD for three years or more. Figs 3a and 3b show
the sequential motor and sensory conduction velocities in these patients. Linear
regression analysis of nerve conduction velocity as a function of time showed no
significant change following dialysis. Motor nerve conduction velocitiesindiabetic
patients also remained unchanged. These data suggest that peripheral neuro-
pathy does not progress in patients on CAPD for prolonged periods. Contrary to
our findings, Lindholm et a141 showed that peripheral neuropathy may worsen
during CAPD. However, the presence in their study of a marked predominance of
males may have influenced their results, because men are more prone to uraemic
neuropathy than women.42
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Fig. 3a. Sequential motor conduction velocities
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Fig. 3b. Sequential sensory nerve
conduction velocities in non-
diabetic patients on CAPD for more
than three years.
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Cognitive function
A large proportion of patients with advanced renal failure have a significant
degree of cognitive dysfunction which is attributed to neurotoxicity before treat-
ment. Kenny43 developed an 'impairment index' to assess cognitive dysfunction
in individual CAPD patients. This index, which ranges from 0.0 (no impairment)
to 1.0 (severe impairment), is calculated on the basis ofeight psychometric tests.
He studied 46 patients over 12 months of CAPD treatment. In the beginning,
only 37 % of them had normal cognitive function (score 0.0-0.2), whereas
22.7% had markedly impaired function (score > 5.0). At the end of one year,
59% had normal cognitive function and the proportion of those with markedly
impaired scores dropped to 13%. The population of non-impaired patients
increases up to 70% after treatment for two years or more.
Renal osteodystrophy
Renal osteodystrophy is a major complication of long-term dialysis. With the
better controlofserum phosphorus, one would expect improvement inthe course
ofrenal osteodystrophyinCAPD patients. So farthe results have been conflicting.
Tielemans et al44 found that osteitis fibrosa progressed in 15 patients who were
on CAPD for 7 to 28 months. Teitelbaum et al45 studied six CAPD patients by
repeated bone biopsies and found that osteomalacia improved whereas the
osteitis fibrosa worsened. Gokal et al46 studied 40 CAPD patients dialysed with a
dialysate calcium of 7 mg/dl and found improvement of both osteomalacia and
osteitis fibrosa during the first year. The parathyroid hormone level declined in
three-quarters of the patients. Digenis et al47 reviewed the radiological evidence
of renal osteodystrophy in 27 patients who had been on CAPD for three years or
more. According to the radiological findings at the beginning of the treatment,
they divided these 27 patients (10 males and 17 females) into two groups:
Group A (10 patients) included those who had no subperiosteal resorption, and
group B (17 patients) those with increased subperiosteal resorption. In group A,
the radiological findings remained normal in 8 and progressed in 2. In group B,
subperiosteal resorption remained unchanged or progressed in 14, while it
improved in the other 3. Plasma PTH levels paralleled the radiological changes.
Ofthe 27, 7 developed spontaneous fractures which, however, healed with callus
formation. Thus secondary hyperparathyroidism persists in patients on long-term
CAPD in our experience; this may be due to a low dialysate calcium and low oral
calcium intake.
Abnormalities in lipid metabolism
Almost one-half of those on CAPD develop hypertriglyceridaemia, which has
been attributed to the large load ofglucose (150 -200 g) absorbed daily from the
dialysate.
In a prospective study of the effect of three to six months on CAPD48 on serum
lipids, we found that patients with high triglycerides before starting CAPD
continued to have high levels, which, in some, rose even further. The VLDL
cholesterol also increased whereas HDL cholesterol did not change. Serum
triglyceride and cholesterol levels remained normal in those who had normal lipid
profiles at the start of CAPD. After three to six months of CAPD, the HDL
cholesterol increased significantly in this group. Lindholm et al49 also found that
the serum lipids remained normal in a large proportion of their CAPD patients.
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Hypotension and peripheral vascular disease
CAPD controls blood pressure so effectively that occasionally these patients
develop orthostatic hypotension. Brown et al50 reported that a drop in the
systemic blood pressure and in the already impaired perfusion of the ischemic
limbs could exacerbate symptoms of peripheral vascular disease. It may be
necessary to remove patients from CAPD and allow their blood pressure to
increase so as to alleviate the symptoms ofperipheral vascular disease. Leenen et
a151 studied 5 symptomatic, hypotensive patients before and after oral salt
loading, during which they did not allow a concomitant increase of body weight.
The patients received between 85 and 170 mmol of sodium per day in addition
to the original daily intake. Salt-loading lasted two to three weeks. Supine blood
pressure increased markedly after salt loading, from 94/67 mmHg to 121/78
mmHg, and the symptoms of orthostatic hypotension disappeared. Salt-loading
appears to confer its benefits by increasing extracellular fluid volume and
sympathetic tone, as assessed by plasma norepinephrine levels and the pressor
responsiveness to norepinephrine.
Causes ofdeath
Of 257 patients on our CAPD programme, 42 had died. Sixteen died of cardio-
vascular causes and 10 died suddenly. We believe that most of the latter died of
cardiac causes, because most of them had evidence of cardiac abnormalities on
routine tests before death and none had electrolyte disturbances. Thus cardlo-
vascular deaths accounted for more than one-half ofthe deaths on CAPD. Seven
patients died of peritonitis. They either had a Staphylococcus aureus infection or
faecal peritonitis due to perforation ofviscus. The remaining 9 deaths were due to
causes such as pancreatitis, withdrawal from dialysis and malignancies.
COMPARISON OF THE COSTS OF THE VARIOUS MODES OF DIALYSIS
The most expensive part of any dialysis therapy is the services of medical
personnel and the provision of equipment. CAPD achieves the most effective
reduction in labour costs because the patient carries out the entire procedure.
This mode requires only minimal equipment. The Toronto ESRD Task Force has
calculated that (per patient year) CAPD costs much less than centre peritoneal
dialysis and haemodialysis.52 It is also cheaperthan home dialysis.52,53 In Toronto
(1983) CAPD costs Can $15,000 per patient year compared with Can $27,000
for centre haemodialysis and Can $18,000 for home haemodialysis.
Most centres refer patients of advanced age and those with cardiovascular
diseases to the CAPD programme because it achieves a stable haemodynamic
and biochemical condition. These patients tend to have multiple medical
problems and hence to require frequent admissions which invariably add to the
total cost of CAPD.
Even though CAPD isless expensive than hospitalorfacility based haemodialysis,
itstill remains relatively expensive and weshould continue oureffortsto lowerthe
cost of dialysis solutions - the main expense. We can reduce the cost of CAPD
by decreasing thefrequency ofexchanges from fourto three perday, using either
2 or 3 litre bags. This modification would lower the total cost of dialysis solution
but also would reduce the cost ofperitonitis treatment, because the frequency of
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peritonitis is much lower in those using three exchanges per day.54 At a time
when economic resources are limited, reducing the cost of renal replacement
therapy toa minimum will enable physicians to treat more patientswith end-stage
renal failure.
CONCLUSION
As this paper explains, CAPD provides adequate removal of metabolic wastes,
ameliorates someofthe common long-term complications and restores disturbed
physiology towards normal in end-stage renal failure. Thus CAPD is an important
treatment for patients with end-stage renal disease. While it is the treatment of
choice for some patients it may not be tolerated by others who then will be
maintained by haemodialysis. Centres which cannot provide both haemodialysis
and CAPD with equally high standards function under a considerable handicap.
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